Video Shorts

Unpacking Patient-Reported Outcomes in IMvigor011

Explaining the Next Steps for Studying Ipatasertib Plus Pembrolizumab in HNSCC

Important Expectations With Later Lines of Therapy in Older Patients with CLL

Exploring HSV-Based Immunotherapy in Advanced NSCLC

Appropriately Integrating AI Tools Into Breast Pathology Practices

Targeting CALR Mutations in MPNs

Examining Disease Recurrence in Postpartum Breast Cancer

How Can Data From PSMAtrack Inform Treatment in mHSPC?

How Daraxonrasib Is Shaping the Next Wave of RAS Inhibition in PDAC

The Significance of the MajesTEC-9 Trial in R/R Myeloma

Examining the Safety Profile of Detalimogene Voraplasmid in NMIBC

Who's Who? With Two Onc Docs!

ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Despina Siolas, MD, PhD

Noting the Clinical Relevance of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

Highlighting KEYNOTE-522 Data With Pembrolizumab in TNBC

Assessing Data for In Vivo CAR T-Cell Therapy in Myeloma

Examining the Implications of the VIKTORIA-1 Study 2 Data in PIK3CA-Mutated Breast Cancer

Explaining the Prognostic Implications of Post-Surgical ctDNA Status in Early TNBC

Exploring the Potential Role of AI-Augmented Surgery in CRC

ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Matthew Nguyen, MD

Assessing Luspatercept Data for Anemia in Myelofibrosis

Highlighting the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer

Spotlighting the BRIA-ABC Trial of Bria-IMT in Metastatic Breast Cancer

Highlighting the DESTINY-Breast09 Trial of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

Integrating Adjuvant Belzutifan Plus Pembrolizumab into the ccRCC Treatment Paradigm

Examining the Potential Role of Aglatimagene Besadenovec in Prostate Cancer

Pathology or Pastry at WCCL 2026!

Seeing if Experts Can Get on the Same Wavelength at WCCL 2026!

ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Dr Manju George

Stopping Mogamulizumab Treatments in Patients with SS After Achieving CR